Title:
COMBINATION METHODS OF TREATING CANCER
Document Type and Number:
WIPO Patent Application WO2005023179
Kind Code:
A3
Abstract:
The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
More Like This:
Inventors:
BACOPOULOS NICHOLAS G (US)
CHIAO JUDY H (US)
MARKS PAUL A (US)
MILLER THOMAS A (US)
PARADISE CAROLYN M (US)
RICHON VICTORIA M (US)
RIFKIND RICHARD A (US)
CHIAO JUDY H (US)
MARKS PAUL A (US)
MILLER THOMAS A (US)
PARADISE CAROLYN M (US)
RICHON VICTORIA M (US)
RIFKIND RICHARD A (US)
Application Number:
PCT/US2004/026161
Publication Date:
June 16, 2005
Filing Date:
August 12, 2004
Export Citation:
Assignee:
ATON PHARMA INC (US)
SLOAN KETTERING INST CANCER (US)
BACOPOULOS NICHOLAS G (US)
CHIAO JUDY H (US)
MARKS PAUL A (US)
MILLER THOMAS A (US)
PARADISE CAROLYN M (US)
RICHON VICTORIA M (US)
RIFKIND RICHARD A (US)
SLOAN KETTERING INST CANCER (US)
BACOPOULOS NICHOLAS G (US)
CHIAO JUDY H (US)
MARKS PAUL A (US)
MILLER THOMAS A (US)
PARADISE CAROLYN M (US)
RICHON VICTORIA M (US)
RIFKIND RICHARD A (US)
International Classes:
A61K31/19; A61K31/44; A61K; (IPC1-7): A61K31/44; A61K31/19
Foreign References:
| US20040116407A1 | 2004-06-17 | |||
| US6811788B2 | 2004-11-02 | |||
| US20030235588A1 | 2003-12-25 | |||
| US20030059812A1 | 2003-03-27 | |||
| US5369108A | 1994-11-29 | |||
| US6511990B1 | 2003-01-28 | |||
| US20030096777A1 | 2003-05-22 | |||
| US20030114525A1 | 2003-06-19 | |||
| US20030144340A1 | 2003-07-31 |
Other References:
BUTLER L.M. ET AL.: "The histone deacetylase inhibitor SAHA arests cancer cell growth, up regulates thioredoxin-binding-protein-2, and down-regulates thioredoxin", PROC NATL ACAD SCI, vol. 99, no. 18, 3 September 2002 (2002-09-03), pages 11700 - 11705, XP008098510
CASTRO-GALACHE M.D. ET AL: "Suspectibility of multidrug resistance tumor cells tot apoptosis induction by histone deacetylase inhibitors", INT J CANCER, vol. 104, 2003, pages 579 - 586, XP008098632
HENDERSON C. ET AL.: "Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (HSA)", J BIOL CHEM, vol. 278, no. 14, 4 April 2003 (2003-04-04), pages 12579 - 12589, XP008098506
ZHU W.G. ET AL: "The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells", CURR MED CHEM - ANTI-CANCER AGENTS, vol. 3, no. 3, 2003, pages 187 - 199, XP008022883
PEART M.J.: "Novel mechanisms of apoptosis induced histone deacetylase inhibitors", CANCER RESEARCH, vol. 63, 1 August 2003 (2003-08-01), pages 4460 - 4471, XP008098631
KELLY W.K. ET AL: "Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously", CLINICAL CANCER RESEARCH, vol. 9, no. 10, 1 September 2003 (2003-09-01), pages 3587 - 3588, XP008098505
KIM. M.S. ET AL.: "Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA", CANCER RESEARCH, vol. 63, 1 November 2003 (2003-11-01), pages 7291 - 7300, XP002486777
See also references of EP 1667680A4
CASTRO-GALACHE M.D. ET AL: "Suspectibility of multidrug resistance tumor cells tot apoptosis induction by histone deacetylase inhibitors", INT J CANCER, vol. 104, 2003, pages 579 - 586, XP008098632
HENDERSON C. ET AL.: "Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (HSA)", J BIOL CHEM, vol. 278, no. 14, 4 April 2003 (2003-04-04), pages 12579 - 12589, XP008098506
ZHU W.G. ET AL: "The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells", CURR MED CHEM - ANTI-CANCER AGENTS, vol. 3, no. 3, 2003, pages 187 - 199, XP008022883
PEART M.J.: "Novel mechanisms of apoptosis induced histone deacetylase inhibitors", CANCER RESEARCH, vol. 63, 1 August 2003 (2003-08-01), pages 4460 - 4471, XP008098631
KELLY W.K. ET AL: "Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously", CLINICAL CANCER RESEARCH, vol. 9, no. 10, 1 September 2003 (2003-09-01), pages 3587 - 3588, XP008098505
KIM. M.S. ET AL.: "Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA", CANCER RESEARCH, vol. 63, 1 November 2003 (2003-11-01), pages 7291 - 7300, XP002486777
See also references of EP 1667680A4
Download PDF:
Previous Patent: ACRIDONE DERIVATIVES AS ANTI-HERPESVIRUS AGENTS
Next Patent: METHOD FOR DETECTING CANCER CELLS AND MONITORING CANCER THERAPY
Next Patent: METHOD FOR DETECTING CANCER CELLS AND MONITORING CANCER THERAPY